Skip to content
Educational information only. Not medical advice. We sell nothing and take no affiliate money.
By /
PeptideMostly animalNot FDA approved

FOXO4-DRI

FOXO4 D retro inverso peptide

Last reviewed October 27, 2026 · 18 sources · Written for general readers · Compare with another compound →

The bottom line

FOXO4-DRI is an experimental peptide designed to kill senescent cells, the worn out cells that build up with age. In mice it improved fitness, fur, kidney function, testosterone and blood vessel aging, but one mouse study found that clearing such cells made a lung blood pressure disease worse. No one has published a human study of it, and a 2026 review notes it has never been validated in people.

Where the evidence stands

What it is

FOXO4-DRI is a short synthetic peptide built in a laboratory. It is a mirror image copy of a piece of a human protein called FOXO4, joined to a carrier sequence that helps it get inside cells. Scientists at Erasmus MC in the Netherlands first described it in 2017.[1]

Mirror image here means it is built entirely from D amino acids, the reverse handed form of the building blocks the body normally uses.[2]

It belongs to a group of experimental compounds called senolytics. Senolytics are meant to kill senescent cells, which are cells that have stopped dividing but refuse to die and leak signals that irritate nearby tissue.[1]

It is not a medicine. No health agency has approved it, and it is not on FDA's list of substances nominated for pharmacy compounding.[3]

Name
FOXO4-DRI (FOXO4 D retro inverso peptide)
Other names
FOXO4 p53 interfering peptide, proxofim
Type
Peptide

What it does in the body

FOXO4-DRI does not occur naturally. Its target is a partnership between two natural proteins: FOXO4, which helps worn out cells survive, and p53, the body's main switch for making damaged cells self destruct.[1] The peptide breaks up that partnership so p53 can push senescent cells to die.[4] All evidence comes from cells and animals.

This is the biology, area by area. A change measured in the body, like a higher blood level, does not always mean a person feels a benefit. The claims check below covers that.

Energy and cells

Lab finding

In senescent cells, FOXO4 holds p53 inside the cell nucleus and keeps it from triggering cell death. FOXO4-DRI gets in the way, p53 leaves the nucleus, and the senescent cell dies, while healthy cells are much less affected.[1] Structure studies show the peptide grabs a floppy part of p53 more tightly than natural FOXO4 does.[4]

Kidneys

Seen in animals

In fast aging mice and naturally old mice, treatment improved kidney function, along with fitness and fur density.[1]

Hormones

Seen in animals

In naturally aged mice, the peptide cleared worn out Leydig cells, the cells in the testes that make testosterone, and eased the age related drop in testosterone.[5] A 2024 study in aged mice found better sperm production.[6]

Heart and blood vessels

Seen in animals

In naturally aged and fast aging mice, injections of FOXO4-DRI slowed aging of the aorta, the body's main artery, and improved how it worked. In blood vessel lining cells in a dish, it freed p53 and switched on the cell death machinery.[7]

Lungs

Seen in animals

In two mouse studies of lung scarring, FOXO4-DRI reduced the scarring.[8][9] In newborn rats exposed to very high oxygen, a model of a lung disease of premature babies, it reduced senescent cells and improved lung structure.[10] But in a study of high blood pressure in the lungs, clearing senescent cells made the disease worse.[11]

Skin and hair

Seen in animals

Fast aging and old mice grew denser fur after treatment.[1] In keloid scar tissue taken from patients and studied in the lab, the peptide pushed aged scar cells to die.[12]

Joints and tendons

Lab finding

In human cartilage cells grown in a dish, it removed more than half of the aged cells, but the remaining cells did not get better at building new cartilage.[13]

How it works

The idea behind FOXO4-DRI is simple to state, even if the biology is not.

  • Senescent cells stay alive partly because a protein called FOXO4 holds another protein, p53, in the cell nucleus and keeps it from triggering cell death.[1]
  • FOXO4-DRI is designed to get in the way of that grip. When it does, p53 moves out of the nucleus and the senescent cell dies.[1]
  • Laboratory work using nuclear magnetic resonance showed that the peptide binds a floppy region of p53 called the transactivation domain, and binds it more tightly than the natural FOXO4 protein does.[4]
  • Healthy cells are much less affected, which is why researchers call the effect selective.[1]
  • A 2026 review found the FOXO4 and p53 survival link well supported, but notes FOXO4-DRI has not been validated in clinical studies.[14]

The binding story is well studied in test tubes. Whether the same thing happens usefully in a living human body has never been tested.

What the research shows

We keep animal and human evidence apart. A result in animals is a reason to study something in people, not proof that it works in people.

Animal and lab studies

Striking mouse results, plus one warning sign

  • In the first report, the peptide was tolerated in mice and reduced damage caused by doxorubicin, a chemotherapy drug. In fast aging and naturally old mice, it improved fitness, fur density and kidney function.[1]
  • In naturally aged mice, it targeted senescent Leydig cells, which make testosterone, and eased the age related drop in testosterone.[5] A later study in aged mice found better sperm production.[6]
  • In naturally aged and fast aging mice, it slowed aging of the aorta and improved its function.[7]
  • In two mouse studies of lung scarring caused by the drug bleomycin, FOXO4-DRI reduced the scarring.[8][9] In newborn rats raised in very high oxygen, it reduced senescent cells and improved lung structure.[10]
  • A warning sign: a 2023 study of pulmonary hypertension, high blood pressure in the lungs, found that clearing senescent cells made the disease worse in rodents. FOXO4-DRI was used in one mouse model, though most of the work used a different drug.[11]

Limit: Mice are not small people. Most studies are small and do not report how many animals were used, and one shows that removing senescent cells can backfire.

Human studies

There are no human studies of FOXO4-DRI

  • No clinical trial of FOXO4-DRI in people has been published. A 2025 laboratory paper notes that related compounds built from its structure are still in preclinical development, meaning animal and test tube stages.[4]
  • A 2026 review of 89 publications on FOXO4 concluded the peptide has not been clinically validated.[14]
  • Human tissue has been used only in the lab. Keloid scar tissue from patients and cartilage cells from people were treated in dishes, not inside a body.[12][13]
  • Autopsy lungs from babies with a lung disease of prematurity showed more senescent cells, but no baby was treated.[10]
  • A 2026 review of FOXO4 targeting peptides for brain aging mentioned early human studies only for a different compound, fisetin, not FOXO4-DRI.[15]

Limit: With zero human data there is no way to know what the peptide does to a person over days, months or years.

Claims check

The most common claims about this compound, and what studies actually found. Verdicts rate the evidence, not whether you should use it.

Reverses aging by clearing zombie cells

Only in animals

In fast aging mice and naturally old mice, FOXO4-DRI cleared senescent cells and improved fitness, fur density and kidney function.[1] In aged mice it also slowed aging of the main artery.[7] No human has been tested.

Regrows hair

Only in animals

The only evidence is denser fur in fast aging and old mice in the original 2017 study.[1] Hair has never been studied in people.

Raises testosterone and fertility

Only in animals

In naturally aged mice, it targeted worn out testosterone making cells in the testes and eased the age related drop in testosterone.[5] A 2024 study in aged mice found better sperm production.[6] No human data exist.

Boosts fitness and stamina

Only in animals

Fast aging and old mice treated with the peptide showed better fitness in the 2017 study.[1] This has not been tested in people.

Repairs joints and cartilage

Only in animals

In human cartilage cells grown in a dish, it removed more than half of the aged cells, but it did not improve how well the remaining cells built new cartilage.[13] No animal or human joint study was found.

Heals scars and skin

Only in animals

In keloid scar tissue taken from patients and studied in the lab, FOXO4-DRI pushed aged scar cells to die.[12] No one has tested it on scars in living people.

Protects the brain and memory

Only in animals

A 2026 review summarizes animal studies in which the peptide reduced senescent cells and improved blood flow, the brain's blood barrier and memory in aged animals.[15] The only human data it cites are for a different compound, fisetin.

Helps fight cancer

Only in animals

In glioblastoma brain tumor cells in the lab, FOXO4-DRI cleared cells pushed into senescence by the chemotherapy drug temozolomide and made the drug work better.[16] It has never been tested in a person with cancer.

Known risks and side effects

  • Everything is unknown in people. Safety, side effects and interactions have never been measured in a human being. Related compounds remain in preclinical development.[4]
  • Clearing cells can backfire. In a mouse study, removing senescent lung blood vessel cells worsened pulmonary hypertension, a serious lung and heart condition.[11]
  • Killing cells on purpose is not gentle. The peptide works by triggering cell death through p53, a central controller of cell survival and cancer protection. Pushing on that system without human safety data is a real gamble.[1][4]
  • Unregulated products. FOXO4-DRI is not an approved drug anywhere and is not on the FDA list of bulk substances nominated for pharmacy compounding, so anything sold online has no check on identity, purity or sterility.[3]
  • Athletes can be caught out. WADA's 2026 and 2027 lists ban substances with no current approval for human use at all times, in a class called S0, even when the exact name is not printed on the list.[17][18]

Regulatory status

Today: FOXO4-DRI is not an approved medicine in the United States and does not appear on the FDA list of bulk drug substances nominated for pharmacy compounding under section 503A.[3] It is not named on the 2026 or 2027 WADA Prohibited Lists, but the S0 class covers substances with no current approval for human therapeutic use.[17][18]

  1. Dutch researchers publish the first description of the peptide and its effects in mice.[1]
  2. A mouse study finds that clearing senescent cells can worsen pulmonary hypertension.[11]
  3. A structural study maps where the peptide binds p53 and notes related compounds remain in preclinical development.[4]
  4. A review of the FOXO4 research notes the peptide still has no clinical validation.[14]

Sources

  1. Baar MP, Brandt RMC, Putavet DA, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017;169(1):132-147.e16. PMID 28340339
  2. Krimpenfort P, Berns A. Rejuvenation by Therapeutic Elimination of Senescent Cells. Cell. 2017;169(1):3-5. PMID 28340347
  3. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026. FDA 503A nominations list
  4. Bourgeois B, Spreitzer E, Platero-Rochart D, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16(1):5672. PMID 40593617
  5. Zhang C, Xie Y, Chen H, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020;12(2):1272-1284. PMID 31959736
  6. Li Y, Zhang C, Cheng H, Lv L, et al. FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Exp Gerontol. 2024;195:112522. PMID 39025385
  7. Hu Z, Li F, Hu C, et al. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Front Bioeng Biotechnol. 2026;13:1729166. PMID 41625068
  8. Han X, Yuan T, Zhang J, Shi Y, et al. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. J Cell Mol Med. 2022;26(11):3269-3280. PMID 35510614
  9. Liu Y, Hou Q, Wang R, Liu Y, et al. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(10):2393-2403. PMID 37074394
  10. Jing X, Jia S, Teng M, Day BW, Afolayan AJ, Jarzembowski JA, et al. Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia. Am J Respir Cell Mol Biol. 2024;70(2):94-109. PMID 37874230
  11. Born E, Lipskaia L, Breau M, Houssaini A, et al. Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression. Circulation. 2023;147(8):650-666. PMID 36515093
  12. Kong YX, Li ZS, Liu YB, Pan B, et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025;8(1):299. PMID 39994346
  13. Huang Y, He Y, Makarcyzk MJ, Lin H. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021;9:677576. PMID 33996787
  14. Mateescu DM, Gavrilescu DM, Marinescu AR, et al. FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. Antioxidants (Basel). 2026;15(7):842. PMID 42510573
  15. Alameen AAM, Al-Kuraishy HM, Fawzy MN, Batiha GE, et al. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn Schmiedebergs Arch Pharmacol. 2026;399(10):14659-14676. PMID 42024235
  16. Ning N, Wang C, Gao T, et al. Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence. Mol Carcinog. 2026;65(9):1092-1104. PMID 42391447
  17. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. Effective January 1, 2026. WADA 2026 Prohibited List
  18. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. Comes into effect January 1, 2027. WADA 2027 Prohibited List
Medical disclaimer

This page is educational information only. It is not medical advice and does not replace care from a licensed medical provider. Do not use this page to decide whether to take any substance. Talk to a licensed medical provider first.

Found an error or a newer study? We correct pages fast.

Report a correction →
Scroll to Top